Ann: Investor Presentation - Non-deal Roadshow, page-31

Hello Comincon,

You sound frustrated - and you've made a few assumptions which I'm curious about. I'm pretty sure Terrascend has already purchased Ilera Healthcare - details of the transaction here.

https://www.terrascend.com/acquisition-ilera-healthcare/

There were some performance-based bonus payments in the contract based on revenue, but I can't find anything to suggest that the deal wasn't completed as per the Terrascend updates. https://www.terrascend.com/completes-acquisition-ilera-healthcare/

If you've got some extra info, I'd be interested in reading it.

In regards to revenue and share price, what impact will the Opioid trial have? Fingers crossed it's enormous, but it's a phase 1 trial of 10 people. Ten people who took more than six months to find via two different organisations.

Let's hope it's successful, happy days and maybe a bump to the SP. But how long will it take to find enough people to do a phase 2 study - years if phase 1 is anything to go by. The opioid trial is a worthy cause, but at best its a partnership opportunity IMO.

My understanding of today's presentation is that its an update for Hope and Zenivol. And that there will be an investor call/video later this month to update shareholders with the go-to-market strategies for both products. Which could be an excellent opportunity for holders to ask questions!

Cheers - DYOR and good luck all.

k.